Der Multiple Sclerosis Health Resource Utilization Survey

2021 ◽  
Author(s):  
Nils-Henning Ness ◽  
Dirk Schriefer ◽  
Rocco Haase ◽  
Tjalf Ziemssen
Keyword(s):  
Multiple Sclerosis ◽  
Resource Utilization ◽  
Health Resource ◽  
Health Resource Utilization ◽  
Indirekte Kosten

Zusammenfassung Hintergrund In gesundheitsökonomischen Studien sind valide und verlässliche Kostendaten essentiell, um belastbare Schlussfolgerungen zu ziehen und eine höchstmögliche Versorgungsqualität der Patienten sicherzustellen. Im Falle der Multiplen Sklerose (MS) basieren solche Studien häufig auf Primärdaten, deren zugrundeliegende Erhebungsinstrumente nicht publiziert sind. Zudem erschweren heterogene Methoden die Vergleichbarkeit und Interpretation solcher Studienergebnisse. Zur Vereinheitlichung gesundheitsökonomischer Studien in der MS wurde der Multiple Sclerosis Health Resource Utilization Survey (MS-HRS) entwickelt, validiert und frei zugänglich publiziert. Fragestellung Fokus dieser Übersichtsarbeit bildet der MS-HRS. Wir berichten methodische Grundlagen zur Krankheitskostenerfassung sowie MS-HRS basierte Ergebnisse zu den Kosten der Krankheitsdynamik bei Personen mit MS. Material/Methodik Dieser Artikel beruht auf einer selektiven Literaturrecherche zum MS-HRS und zu den gesundheitsökonomischen Aspekten der Krankheitskostenerfassung. Ergebnisse Der MS-HRS erfasst patientenberichtet die gesellschaftliche Inanspruchnahme von direkten medizinischen, direkten nicht-medizinischen sowie indirekten Ressourcen. Indirekte Kosten werden weiterhin zwischen Absentismus, sowohl kurzzeitig (Krankheitstage) als auch langfristig (Erwerbs-/Berufsunfähigkeit), und Präsentismus unterschieden. Der Ressourcenverbrauch wird mit den gesellschaftlichen Opportunitätskosten approximiert. Erste MS-HRS basierte Analysen zeigen, dass neben dem stationären Behinderungsgrad und dem klinischen Verlauf auch die Krankheitsdynamik in Form von Schüben und Progression enorme sozioökonomische Auswirkungen hat. Diskussion Valide Krankheitskostendaten bringen Transparenz in die ökonomischen Auswirkungen von Erkrankungen. In Ergänzung zu klinischen Daten kann die Kosteneffektivität festgestellt werden und somit Anhaltspunkte für eine effizientere Patientenversorgung aufgedeckt werden. Im Falle der MS steht zur Kostenerfassung ein frei zugängliches Instrument (MS-HRS) zur Verfügung.

scholarly journals The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study (Preprint)

2020 ◽  
Author(s):  
Nils-Henning Ness ◽  
Rocco Haase ◽  
Raimar Kern ◽  
Dirk Schriefer ◽  
Benjamin Ettle ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Resource Utilization ◽  
Discriminant Validity ◽  
Response Rate ◽  
Health Resource ◽  
Health Resource Utilization ◽  
Retest Reliability ◽  
Study Results ◽  
Patient Reported ◽  
Test Retest Reliability

BACKGROUND Survey-based studies are frequently used to describe the economic impact of multiple sclerosis (MS). However, there is no validated health resource survey available, preventing comparison of study results and meaningful conclusions regarding the efficiency of long-term treatments. OBJECTIVE The aim of this study was to develop and validate a tablet- and paper-based MS health resource utilization survey. METHODS We developed and validated the Multiple Sclerosis Health Resource Utilization Survey (MS-HRS), consisting of 24 cost items for paper and tablet users. Data for validation came from two large German observational studies. Survey practicability was assessed according to the response rate. Reliability was described using test-retest reliability as well as Guttman lambda. Construct validity was assessed as convergent and discriminant validity via correlations with associated patient-reported outcomes and known-group analyses. RESULTS In total, 2207 out of 2388 (response rate: 92.4%) patients completed the survey and were included to determine psychometric properties. The test-retest reliability had an intraclass correlation coefficient of 0.828 over a course of 3 months. Convergent validity analyses showed that total costs correlated positively with increased disability (<i>r</i>=0.411, <i>P</i>&lt;.001). For discriminant validity, correlations of total costs with the Treatment Satisfaction Questionnaire for Medication ranged from −0.006 (convenience) to −0.216 (effectiveness). The mean annual cost was €28,203 (SD €14,808) (US $39,203; SD US $20,583) with disease-modifying therapies. CONCLUSIONS The MS-HRS is a multilingual, reliable, valid, electronically available, and easy-to-administer questionnaire providing a holistic cross-sectional and longitudinal assessment of resource utilization in patients with MS.

scholarly journals The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study

10.2196/17921 ◽  
2020 ◽  
Vol 22 (3) ◽  
pp. e17921 ◽  
Author(s):  
Nils-Henning Ness ◽  
Rocco Haase ◽  
Raimar Kern ◽  
Dirk Schriefer ◽  
Benjamin Ettle ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Resource Utilization ◽  
Discriminant Validity ◽  
Response Rate ◽  
Health Resource ◽  
Health Resource Utilization ◽  
Retest Reliability ◽  
Study Results ◽  
Patient Reported ◽  
Test Retest Reliability

Background Survey-based studies are frequently used to describe the economic impact of multiple sclerosis (MS). However, there is no validated health resource survey available, preventing comparison of study results and meaningful conclusions regarding the efficiency of long-term treatments. Objective The aim of this study was to develop and validate a tablet- and paper-based MS health resource utilization survey. Methods We developed and validated the Multiple Sclerosis Health Resource Utilization Survey (MS-HRS), consisting of 24 cost items for paper and tablet users. Data for validation came from two large German observational studies. Survey practicability was assessed according to the response rate. Reliability was described using test-retest reliability as well as Guttman lambda. Construct validity was assessed as convergent and discriminant validity via correlations with associated patient-reported outcomes and known-group analyses. Results In total, 2207 out of 2388 (response rate: 92.4%) patients completed the survey and were included to determine psychometric properties. The test-retest reliability had an intraclass correlation coefficient of 0.828 over a course of 3 months. Convergent validity analyses showed that total costs correlated positively with increased disability (r=0.411, P<.001). For discriminant validity, correlations of total costs with the Treatment Satisfaction Questionnaire for Medication ranged from −0.006 (convenience) to −0.216 (effectiveness). The mean annual cost was €28,203 (SD €14,808) (US $39,203; SD US $20,583) with disease-modifying therapies. Conclusions The MS-HRS is a multilingual, reliable, valid, electronically available, and easy-to-administer questionnaire providing a holistic cross-sectional and longitudinal assessment of resource utilization in patients with MS.

scholarly journals 195. Economic and Clinical Burden of Respiratory Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S226-S226
Author(s):  
Michael G Ison ◽  
Nelson Chao ◽  
Francisco M Marty ◽  
Seung Hyun Moon ◽  
Zhiji Zhang ◽  
...  
Keyword(s):  
Resource Utilization ◽  
Research Study ◽  
Viral Infections ◽  
Scientific Research ◽  
Health Resource ◽  
Health Resource Utilization ◽  
Allogeneic Hct ◽  
Study Investigator ◽  
Respiratory Viral Infections ◽  
One Year

Abstract Background Respiratory viruses (RV), including respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (HMPV), frequently lead to serious complications such as lower respiratory tract infections and death in allogeneic hematopoietic cell transplantation (HCT) recipients. We used a large US claims database to compare the total reimbursement (TR), health resource utilization (HRU) and clinical outcomes between HCT patients with and without RV infections (RVI). Methods We used the Decision Resources Group Real World Evidence Data Repository to identify HCT recipients with date of service for the procedure from 1/1/2012-12/31/2017. We estimated the reimbursements from submitted charges using a reimbursement to charge ratio of 0.425. We examined the study outcomes in the year following HCT in patients with and without RVI. We also used a generalized linear model to determine adjusted TR stratified by the presence or absence of any acute or chronic graft-versus-host diseases (GVHD) after adjusting for age, health plan, underlying disease, stem cell source, number of comorbidities, baseline costs, and follow-up time. Results The study included 13,363 patients, representing 22% of HCTs reported to CIBMTR for the study period, of which 1,368 (10%) were coded with an RVI in the year following HCT: 578 (4%) RSV, 687 (5%) influenza, 166 (1%) PIV, and 181 (1%) HMPV. Unadjusted median TR were $132,395 higher for any RVI ($139,439 RSV, $101,963 influenza, $185,041 PIV and $248,029 HMPV) compared to those without RVI (Table 1). Adjusted TR were significantly higher for patients with any RVI compared to patients without that infection (p&lt; .01) with or without GVHD (Figure 1). Patients with any RVI had significantly longer length of stay (LOS) for the HCT hospitalization, readmission rate and LOS after HCT hospitalization compared to patients without RVI (p&lt; 0.05) (Table 2). A significantly higher proportion of patients with any RVI had pneumonia as compared to patients without that infection, irrespective of presence of GVHD (p&lt; .0001). Table 1: Total healthcare reimbursement within one year of undergoing allogeneic HCT for patients with and without respiratory viral infections Figure 1: Adjusted total reimbursements within one year of undergoing allogeneic HCT for patients with and without respiratory viral infections Table 2: Health resource utilization within one year of undergoing allogeneic HCT for patients with and without respiratory viral infections Conclusion Allogeneic HCT patients with RVI have a significantly higher burden of TR, health resource utilization and worse clinical outcomes such as pneumonia during one year of undergoing HCT, regardless of the presence of GVHD. Disclosures Michael G. Ison, MD MS, AlloVir (Consultant) Francisco M. Marty, MD, Allovir (Consultant)Amplyx (Consultant)Ansun (Scientific Research Study Investigator)Avir (Consultant)Cidara (Scientific Research Study Investigator)F2G (Consultant, Scientific Research Study Investigator)Kyorin (Consultant)Merck (Consultant, Grant/Research Support, Scientific Research Study Investigator)New England Journal of Medicine (Other Financial or Material Support, Honorarium for Video)Regeneron (Consultant, Scientific Research Study Investigator)ReViral (Consultant)Scynexis (Scientific Research Study Investigator)Symbio (Consultant)Takeda (Scientific Research Study Investigator)United Medical (Consultant)WHISCON (Scientific Research Study Investigator) Seung Hyun Moon, MD, MPA, AlloVir (Employee, Shareholder) Zhiji Zhang, MS, AlloVir (Independent Contractor) Aastha Chandak, PhD, AlloVir (Independent Contractor)

Sign in / Sign up

Export Citation Format

Share Document